Severe aortic stenosis, also known as heart valve failure, is dangerous and delaying treatment can be deadly.

TAVR is a less invasive treatment option and should be considered for those with heart valve failure and have symptoms. With TAVR, patients have a shorter recovery time and most patients return home the next day.

Choose TAVR with the SAPIEN 3 family of valves, which has similar durability as the leading surgical valve at 5 years.1†

It is important to know not all TAVR valves are made the same. Your valve choice matters.

Ask your doctor for a TAVR evaluation and if the SAPIEN 3 Ultra RESILIA valve is right for you.

† Propensity matched analysis of intermediate risk patients using VARC3 definitions of SVD and SVD related BVF at 5 years.

Free TAVR info kit

Get your free TAVR Info Kit now!

What you’ll receive in your kit:

  • Education on severe aortic stenosis and symptoms checklist once it becomes severe
  • Information on TAVR as a treatment option
  • Videos of patients sharing their experiences with TAVR
  • Discussion guide for talking with your doctor
  • List of hospitals in your area that perform TAVR
Hospital

TAVR with SAPIEN 3 family of valves, has similar durability to that of the leading surgical valves at 5 years.1†

The Edwards SAPIEN 3 family of valves are specifically designed with patients in mind, with better clinical outcomes than open heart surgery.§

Edwards’ newest valve, the SAPIEN 3 Ultra RESILIA valve uses bovine (cow) heart tissue that has been treated with a special Edwards technology to block calcium build-up on the valve, potentially allowing the valve to last longer.2‡

Both the SAPIEN 3 Ultra RESILIA valve and the leading surgical valves use RESILIA tissue, known to block calcium build-up on the tissue, which could potentially allow the valve to last longer.2‡

Previously, RESILIA tissue was only approved to be used on surgical heart valves.2‡

The SAPIEN 3 Ultra RESILIA valve is the only TAVR valve with RESILIA tissue2‡

† Propensity matched analysis of intermediate risk patients using VARC3 definitions of SVD and SVD related BVF at 5 years.
‡ RESILIA tissue has not been studied for long-term results in patients.
§ The PARTNER 3 Trial, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint of all-cause death, all stroke, and re-hospitalization (valve-related or procedure-related and including heart failure) at one year, and multiple pre-specified secondary endpoints in low risk patients.

Benefits of TAVR may include:

Improved heart function

Most patients go home the next day and recover quicker

Relief of symptoms

Less pain and anxiety

Improved quality of life following the procedure

Minimal scarring


The most serious risks of TAVR include death, stroke, serious damage to the arteries, or serious bleeding.

How does TAVR compare to open heart surgery?

See how TAVR compares to open heart surgery:

References
1. Pibarot P, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprosthesis in PARTNER-2 trial. J Am Coll Cardiol. 2020; 76: 1830-184 3.
2. Flameng et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015; 149:340-5.
3. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-705.
4. Baron SJ, Magnuson EA, Lu M, et al. Health status after transcatheter versus surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Card. 2019;74:2833-42.
5. Cleveland Clinic. “Transcatheter Aortic Valve Replacement (TAVR).” https://my.clevelandclinic.org/health/treatments/17570-transcatheter-aortic-valve-replacement-tavr. Accessed April 28, 2022.
6. Otto CM. Timing of aortic valve surgery. Heart. 2000;84(2):211-8.
7. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Card. 2021;77:1149-61.